Objective: To identify socio-demographic characteristics of the first patients receiving a new drug-rofecoxib. Outcome measurement: Patients starting on rofecoxib or another non-steroidal anti-inflammatory drug (NSAID) and who had not received any NSAIDs the 90 days prior to starting. Results: Starting on rofecoxib was associated with an increasing age (OR in age 80 years and older 8.7; 95% CI 6.7–11.2), a poor self-perceived health (OR=2.4; 95% CI 1.8–3.3), female gender (OR=1.4; 95% CI 1.2–1.6), private insurance (OR=1.3; 1.1–1.5) and previous acetaminophen use (OR=1.3; 1.1–1.7). Conclusion: This study noted that specific patient characteristics were associated with getting rofecoxib prescribed shortly after marketing. General practition...
Background: Pharmacovigilance is an important tool to gather real-life information on effectiveness ...
Cyclooxygenase-2 inhibitor (COX-2) inhibitors were publicly subsidized in Australia for osteoarthrit...
Background: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and th...
Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxi
The first Cox-2 selective non-steroidal anti-inflammatory drug (NSAID) in the UK, rofecoxib (Vioxx),...
BACKGROUND: The cyclooxygenase-2 (COX-2) inhibitor rofecoxib was registered in 1999. By 2000, the fi...
OBJECTIVE: To gain insight into the trends in the prescription ofrofecoxib, the medication and disea...
OBJECTIVE: To gain insight into the trends in the prescription ofrofecoxib, the medication and disea...
BACKGROUND: The cyclooxygenase-2 (COX-2) selective nonsteroidal antiinflammatory drugs (NSAIDs) cel...
Aim. This study was undertaken to increase understanding of the utilization of a newly introduced st...
Background: When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines di...
Objective. To gain insight into the trends in the prescription of rofecoxib, the medication and dise...
Introduction There is no consistent definition of prescribers who adopt new drug treatments early. T...
Non-steroidal anti-inflammatory drugs (NSAIDs) have frequently been linked with unpleasant gastroint...
PURPOSE: To describe the characteristics of users of cyclo-oxygenase (COX)-2 inhibitors and trad...
Background: Pharmacovigilance is an important tool to gather real-life information on effectiveness ...
Cyclooxygenase-2 inhibitor (COX-2) inhibitors were publicly subsidized in Australia for osteoarthrit...
Background: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and th...
Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxi
The first Cox-2 selective non-steroidal anti-inflammatory drug (NSAID) in the UK, rofecoxib (Vioxx),...
BACKGROUND: The cyclooxygenase-2 (COX-2) inhibitor rofecoxib was registered in 1999. By 2000, the fi...
OBJECTIVE: To gain insight into the trends in the prescription ofrofecoxib, the medication and disea...
OBJECTIVE: To gain insight into the trends in the prescription ofrofecoxib, the medication and disea...
BACKGROUND: The cyclooxygenase-2 (COX-2) selective nonsteroidal antiinflammatory drugs (NSAIDs) cel...
Aim. This study was undertaken to increase understanding of the utilization of a newly introduced st...
Background: When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines di...
Objective. To gain insight into the trends in the prescription of rofecoxib, the medication and dise...
Introduction There is no consistent definition of prescribers who adopt new drug treatments early. T...
Non-steroidal anti-inflammatory drugs (NSAIDs) have frequently been linked with unpleasant gastroint...
PURPOSE: To describe the characteristics of users of cyclo-oxygenase (COX)-2 inhibitors and trad...
Background: Pharmacovigilance is an important tool to gather real-life information on effectiveness ...
Cyclooxygenase-2 inhibitor (COX-2) inhibitors were publicly subsidized in Australia for osteoarthrit...
Background: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and th...